Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 265

1.

Renal Toxicity of Concomitant Exposure to Tenofovir and Inhibitors of Tenofovir's Renal Efflux Transporters in Patients Infected With HIV Type 1.

Rokx C, Alshangi H, Verbon A, Zietse R, Hoorn EJ, Rijnders BJ.

J Infect Dis. 2016 Feb 15;213(4):561-8. doi: 10.1093/infdis/jiv466. Epub 2015 Sep 23.

PMID:
26401025
2.

Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients.

Huang YS, Chan CK, Tsai MS, Lee KY, Lin SW, Chang SY, Hung CC, Chang SC.

J Microbiol Immunol Infect. 2017 Oct;50(5):595-603. doi: 10.1016/j.jmii.2015.08.019. Epub 2015 Sep 9.

3.

Effect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1-Infected Treatment-Naïve Asian Patients: Results from 12-Year Observational Cohort.

Suzuki S, Nishijima T, Kawasaki Y, Kurosawa T, Mutoh Y, Kikuchi Y, Gatanaga H, Oka S.

AIDS Patient Care STDS. 2017 Mar;31(3):105-112. doi: 10.1089/apc.2016.0286.

4.

Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir.

Casado JL, Bañón S, Santiuste C, Serna J, Guzman P, Tenorio M, Liaño F, del Rey JM.

AIDS. 2016 Jan;30(2):231-9. doi: 10.1097/QAD.0000000000000901.

PMID:
26684820
5.
6.

Is Abnormal Urine Protein/Osmolality Ratio Associated with Abnormal Renal Function in Patients Receiving Tenofovir Disoproxil Fumarate?

Marcelin JR, Berg ML, Tan EM, Amer H, Cummins NW, Rizza SA.

PLoS One. 2016 Feb 12;11(2):e0149562. doi: 10.1371/journal.pone.0149562. eCollection 2016.

7.

Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.

Aurpibul L, Cressey TR, Sricharoenchai S, Wittawatmongkol O, Sirisanthana V, Phongsamart W, Sudjaritruk T, Chokephaibulkit K.

Pediatr Infect Dis J. 2015 Apr;34(4):392-7. doi: 10.1097/INF.0000000000000633. Erratum in: Pediatr Infect Dis J. 2015 Aug;34(8):847.

PMID:
25760566
8.

HIV Infection, Tenofovir, and Urine α1-Microglobulin: A Cross-sectional Analysis in the Multicenter AIDS Cohort Study.

Jotwani V, Scherzer R, Estrella MM, Jacobson LP, Witt MD, Palella FJ Jr, Macatangay B, Bennett M, Parikh CR, Ix JH, Shlipak MG.

Am J Kidney Dis. 2016 Oct;68(4):571-581. doi: 10.1053/j.ajkd.2016.03.430. Epub 2016 Jun 8.

9.

Acute Kidney Injury, Risk Factors, and Prognosis in Hospitalized HIV-Infected Adults in South Africa, Compared by Tenofovir Exposure.

Seedat F, Martinson N, Motlhaoleng K, Abraham P, Mancama D, Naicker S, Variava E.

AIDS Res Hum Retroviruses. 2017 Jan;33(1):33-40. doi: 10.1089/AID.2016.0098. Epub 2016 Sep 7.

10.

Urinary β2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy.

Nishijima T, Kurosawa T, Tanaka N, Kawasaki Y, Kikuchi Y, Oka S, Gatanaga H.

AIDS. 2016 Jun 19;30(10):1563-71. doi: 10.1097/QAD.0000000000001070.

PMID:
26919734
11.

Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.

Pontrelli G, Cotugno N, Amodio D, Zangari P, Tchidjou HK, Baldassari S, Palma P, Bernardi S.

BMC Infect Dis. 2012 Jan 23;12:18. doi: 10.1186/1471-2334-12-18.

12.

Acute kidney injury KDIGO stage 2 to 3 in HIV-positive patients treated with cART--a case series over 11 years in a cohort of 1,153 patients.

Kurz M, Burkhalter F, Dickenmann M, Hopfer H, Mayr M, Elzi L, Battegay M.

Swiss Med Wkly. 2015 May 29;145:w14135. doi: 10.4414/smw.2015.14135. eCollection 2015.

13.

Changes in Kidney Function and in the Rate of Tubular Dysfunction After Tenofovir Withdrawal or Continuation in HIV-Infected Patients.

Casado JL, Del Rey JM, Bañón S, Santiuste C, Rodriguez M, Moreno A, Perez-Elías MJ, Liaño F, Moreno S.

J Acquir Immune Defic Syndr. 2016 Aug 1;72(4):416-22. doi: 10.1097/QAI.0000000000000986.

PMID:
26962850
14.

Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.

Mills A, Crofoot G, Ortiz R, Rashbaum B, Towner W, Ward D, Brinson C, Kulkarni R, Garner W, Ebrahimi R, Cao H, Cheng A, Szwarcberg J.

HIV Clin Trials. 2014 Mar-Apr;15(2):51-6. doi: 10.1310/hct1502-51.

PMID:
24710918
15.

Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up.

Nishijima T, Kawasaki Y, Tanaka N, Mizushima D, Aoki T, Watanabe K, Kinai E, Honda H, Yazaki H, Tanuma J, Tsukada K, Teruya K, Kikuchi Y, Gatanaga H, Oka S.

AIDS. 2014 Aug 24;28(13):1903-10. doi: 10.1097/QAD.0000000000000347.

PMID:
25259702
16.

Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.

Quesada PR, Esteban LL, García JR, Sánchez RV, García TM, Alonso-Vega GG, Ferrández JS.

Int J Clin Pharm. 2015 Oct;37(5):865-72. doi: 10.1007/s11096-015-0132-1. Epub 2015 May 26.

PMID:
26008219
17.

Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.

Jose S, Hamzah L, Campbell LJ, Hill T, Fisher M, Leen C, Gilson R, Walsh J, Nelson M, Hay P, Johnson M, Chadwick D, Nitsch D, Jones R, Sabin CA, Post FA; UK Collaborative HIV Cohort Study Steering Committee.

J Infect Dis. 2014 Aug 1;210(3):363-73. doi: 10.1093/infdis/jiu107. Epub 2014 Feb 28.

18.

The significance of antiretroviral-associated acute kidney injury in a cohort of ambulatory human immunodeficiency virus-infected patients.

Wikman P, Safont P, Del Palacio M, Moreno A, Moreno S, Casado JL.

Nephrol Dial Transplant. 2013 Aug;28(8):2073-81. doi: 10.1093/ndt/gft210. Epub 2013 Jun 5.

PMID:
23739150
19.

Tenofovir-Related Nephropathies in HIV-Infected Patients.

Lai S, Mariotti A, Lai C, Testorio M, Carta M, Innico G, Frassetti N, Mangiulli M, D'Angelo A, Russo GE.

Curr Vasc Pharmacol. 2015;13(5):670-5.

PMID:
25412689
20.

Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.

Mugwanya K, Baeten J, Celum C, Donnell D, Nickolas T, Mugo N, Branch A, Tappero J, Kiarie J, Ronald A, Yin M, Wyatt C; Partners PrEP Study Team.

J Infect Dis. 2016 Oct 1;214(7):1050-7. doi: 10.1093/infdis/jiw125. Epub 2016 Mar 29.

Supplemental Content

Support Center